Akagera Medicines
A Rwanda-founded biotechnology company developing liposomal nanotherapeutic formulations of antibacterial small molecules and vaccine candidates to address tuberculosis and other infectious diseases. The company focuses on engineered small-molecule inhibitors, liposome encapsulation for altered biodistribution and extended pharmacokinetics, preclinical efficacy testing including relevant animal models, patent-protected technologies, and collaborative vaccine development with global funders. The company is registered in Delaware, maintains laboratories in the United States, and established a Rwanda subsidiary for future manufacturing and clinical trials.
Industries
Nr. of Employees
small (1-50)
Patents
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
US-12331264-B2
View DetailsOxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof
US-12145928-B2
View DetailsOxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof
US-12116361-B2
View DetailsLipid nanoparticles for delivery of nucleic acids and methods of use thereof
US-12064479-B2
View Details
Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
US-12331264-B2
View DetailsOxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof
US-12145928-B2
View DetailsOxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof
US-12116361-B2
View DetailsLipid nanoparticles for delivery of nucleic acids and methods of use thereof
US-12064479-B2
View DetailsProducts
Long-acting liposomal injectable therapeutic for tuberculosis
A long-acting injectable antibiotic therapeutic using liposome encapsulation aimed at treating MDR/XDR tuberculosis with extended pharmacokinetics and targeted delivery to macrophages.
Liposomal therapeutic candidate for MRSA
Liposomal formulation of an antibacterial agent intended for the treatment of MRSA infections.
Vaccine candidates for multiple infectious diseases
Preclinical vaccine candidates developed for tuberculosis, Lassa fever, HIV, RSV, and influenza, advanced in partnership with international funders and research agencies.
Long-acting liposomal injectable therapeutic for tuberculosis
A long-acting injectable antibiotic therapeutic using liposome encapsulation aimed at treating MDR/XDR tuberculosis with extended pharmacokinetics and targeted delivery to macrophages.
Liposomal therapeutic candidate for MRSA
Liposomal formulation of an antibacterial agent intended for the treatment of MRSA infections.
Vaccine candidates for multiple infectious diseases
Preclinical vaccine candidates developed for tuberculosis, Lassa fever, HIV, RSV, and influenza, advanced in partnership with international funders and research agencies.
Services
Partnership-based development services with philanthropic and public research organizations for preclinical and early clinical development of vaccines and therapeutics.
Partnership-based development services with philanthropic and public research organizations for preclinical and early clinical development of vaccines and therapeutics.
Expertise Areas
- Liposomal drug delivery
- Antibacterial small-molecule discovery
- Vaccine development
- Preclinical in vivo efficacy models
Key Technologies
- Liposomal nanotherapeutics
- Long-circulating liposome formulations
- Small-molecule medicinal chemistry (SAR)
- In vitro cytotoxicity assays
News & Updates
A tuberculosis therapeutic from the company entered Phase I clinical trials in Africa in 2024.
Company hosted a delegation from the European Investment Bank at its Rwandan operations.
Interview discussing the company and Rwanda's potential as a vaccine hub in Africa.
United States Patent Office described the company's technology as novel with wide applicability and invited the company into an expedited process.
A tuberculosis therapeutic from the company entered Phase I clinical trials in Africa in 2024.
Company hosted a delegation from the European Investment Bank at its Rwandan operations.
Interview discussing the company and Rwanda's potential as a vaccine hub in Africa.
United States Patent Office described the company's technology as novel with wide applicability and invited the company into an expedited process.